$557,000 of BECTON DICKINSON AND COMPANY lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to medical technology regulation Issues related to medical device supply chains and supply chain resiliency Issues related to medical device sterilization Issues related to preventative screenings Issues related to maternal health Issues related to corporate taxation Tax incentives for domestic manufacturing Issues related to medical device supply chains and supply chain resiliency Issues related to medical research funding Issues related to medical device sterilization Issues related to medical device supply chain"
You can find more data on corporate lobbying on Quiver Quantitative.
BDX Congressional Stock Trading
Members of Congress have traded $BDX stock 5 times in the past 6 months. Of those trades, 3 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BDX stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 06/17 and 1 sale worth up to $15,000 on 06/24.
- REPRESENTATIVE ROBERT BRESNAHAN has traded it 2 times. They made 1 purchase worth up to $15,000 on 05/15 and 1 sale worth up to $15,000 on 04/08.
- REPRESENTATIVE THOMAS H. KEAN, JR. purchased up to $15,000 on 05/13.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
BDX Insider Trading Activity
BDX insiders have traded $BDX stock on the open market 9 times in the past 6 months. Of those trades, 1 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $BDX stock by insiders over the last 6 months:
- GREGORY HAYES purchased 5,250 shares for an estimated $1,005,742
- CLAIRE FRASER has made 0 purchases and 2 sales selling 1,780 shares for an estimated $337,892.
- MICHAEL DAVID GARRISON (EVP & President, Medical) has made 0 purchases and 3 sales selling 1,664 shares for an estimated $308,141.
- DAVID SHAN (EVP and Chief ISC Officer) sold 1,166 shares for an estimated $199,607
- RICHARD BYRD (EVP & President Interventional) sold 459 shares for an estimated $105,570
- MICHAEL FELD (EVP & President, Life Sciences) sold 57 shares for an estimated $11,285
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BDX Hedge Fund Activity
We have seen 702 institutional investors add shares of BDX stock to their portfolio, and 926 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY removed 4,598,284 shares (-53.5%) from their portfolio in Q2 2025, for an estimated $792,054,419
- VANGUARD GROUP INC added 4,305,947 shares (+15.4%) to their portfolio in Q2 2025, for an estimated $741,699,370
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 3,603,168 shares (+28.7%) to their portfolio in Q2 2025, for an estimated $620,645,688
- BLACKROCK, INC. added 3,389,963 shares (+14.2%) to their portfolio in Q2 2025, for an estimated $583,921,126
- FIRST EAGLE INVESTMENT MANAGEMENT, LLC added 3,268,478 shares (+59.2%) to their portfolio in Q2 2025, for an estimated $562,995,335
- GQG PARTNERS LLC removed 3,011,583 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $518,745,171
- GENERATION INVESTMENT MANAGEMENT LLP removed 2,537,140 shares (-47.9%) from their portfolio in Q2 2025, for an estimated $437,022,365
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BDX Analyst Ratings
Wall Street analysts have issued reports on $BDX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 06/03/2025
- Morgan Stanley issued a "Overweight" rating on 05/06/2025
- Stifel issued a "Buy" rating on 05/02/2025
To track analyst ratings and price targets for BDX, check out Quiver Quantitative's $BDX forecast page.
BDX Price Targets
Multiple analysts have issued price targets for $BDX recently. We have seen 7 analysts offer price targets for $BDX in the last 6 months, with a median target of $200.0.
Here are some recent targets:
- Patrick Wood from Morgan Stanley set a target price of $197.0 on 08/11/2025
- Jason Bednar from Piper Sandler set a target price of $200.0 on 08/08/2025
- Lawrence Biegelsen from Wells Fargo set a target price of $184.0 on 08/08/2025
- Matt Miksic from Barclays set a target price of $241.0 on 06/03/2025
- Joanna Wiensch from Citigroup set a target price of $185.0 on 05/22/2025
- Rick Wise from Stifel set a target price of $224.0 on 05/02/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
